Mankind Pharma Stake Sale: ChrysCapital and Capital Group Divest 7.6% for ₹5,589 Crore

In a significant development, ChrysCapital and Capital Group, two prominent investment firms, have divested a substantial portion of their stake in Mankind Pharma, a leading pharmaceutical company in India. The divestment, executed through open market transactions, involved the sale of a total of 7.6 per cent stake, amounting to Rs 5,589 crore.

Impact on Stock Prices

Following the announcement of the stake sale, shares of Mankind Pharma Ltd witnessed a decline in their value. On the National Stock Exchange (NSE), the stock fell by 3.65 per cent, closing at Rs 1,850 per share. Similarly, on the Bombay Stock Exchange (BSE), the stock experienced a drop of 3.61 per cent, settling at Rs 1,849.45 per share.

Details of the Stake Sale

Beige Ltd, an affiliate of ChrysCapital, sold 4.47 per cent of its stake in Mankind Pharma, while Cairnhill CIPEF and Hema CIPEF I Ltd, affiliates of Capital Group, offloaded a combined 3.14 per cent stake. The bulk deal data revealed that Beige Ltd sold 1,79,10,132 shares on both BSE and NSE, while Cairnhill CIPEF and Hema CIPEF I Ltd sold 1,25,88,400 shares on the NSE.

The shares were sold within a narrow price range of Rs 1,832.30 to Rs 1,832.80 per share, resulting in a combined transaction value of Rs 5,588.71 crore.

Changes in Shareholding Patterns

As a result of the transaction, Beige Ltd's shareholding in Mankind Pharma declined significantly from 7.46 per cent to 2.99 per cent. Similarly, Hema CIPEF I Ltd's stake reduced from 3.63 per cent to 2.23 per cent. Notably, Cairnhill CIPEF exited the company by selling its entire 1.74 per cent stake.

Significant Acquisition on BSE

On the BSE, Kotak Funds India Midcap Fund emerged as a notable acquirer, purchasing 20.29 lakh shares of Mankind Pharma at an average price of Rs 1,832.30 per share. This acquisition amounted to a deal size of Rs 372 crore.

About Mankind Pharma

Established in 1991, Mankind Pharma has established itself as a prominent player in the pharmaceutical industry. The company engages in the development, manufacturing, and marketing of pharmaceutical formulations across various therapeutic areas, including acute and chronic conditions. Additionally, Mankind Pharma offers a range of consumer healthcare products.

The company's branded generic drugs enjoy a strong presence throughout India, particularly in rural and semi-urban markets. Mankind Pharma's successful initial public offering (IPO) in May 2022 further solidified its position as a major player in the domestic pharmaceutical sector.

Conclusion

The divestment of a significant stake in Mankind Pharma by ChrysCapital and Capital Group marks a notable development in the Indian pharmaceutical industry. While the stake sale led to a temporary dip in the company's stock prices, Mankind Pharma's strong market presence and diverse product portfolio position it for continued growth and success in the future.